Abramson J et al. Glofitamab plus gemcitabine and oxaliplatin (Glofit-gemox) for replapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results of a Global randomized phase III trial (STARGLO). EHA 2024;Abstract LB3438.
Allan JN et al. Long-term efficacy and safety of odronextamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL): Pooled analysis from the ELM-1 and ELM-2 studies. ASH 2024;Abstract 3118.
Crombie JL et al. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood 2024;143(16):1565-75. Abstract
Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387(24):2220-31. Abstract
Falchi L et al. Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Updated from phase 1/2 trial. ASCO 2022;Abstract 7524.
Hutchings M et al. Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses of patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume. ASH 2023;Abstract 433.
Jurczak W et al. Longer follow-up from the pivotal EPCORE NHL-1 trial reaffirms subcutaneous epcoritamab induces deep, durable complete remission in patients with relapsed/refractory large B-cell lymphoma. EHA 2023;Abstract P1118.
Karimi Y et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. ASCO 2024;Abstract 7525.
Kim TM et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Ann Oncol 2024;35(11):1039-47. Abstract
Kim W-S et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal phase II study ELM-2. ASH 2022;Abstract 949.
Linton KM et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of as single-arm, multicentre study. Lancet Haematol 2024;11(8):e593-605. Abstract
Lori LA et al. Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7. ASCO 2024;Abstract 7014.
Matasar M et al. Efficacy and safety of odronextamab monotherapy in patients (Pts) with diffuse large B-cell lymphoma (DLBC) progressing after CAR T-cell therapy: Primary analysis from the ELM-1 study. ASH 2024;Abstract 866.
Morschhauser F et al. Preliminary findings of a phase Ib/II trial indicate manageable safety and promising efficacy for mosunetuzumab in combination with lenalidomide (M+Len) in previously untreated (1L) follicular lymphoma (FL). ASH 2023;Abstract 603.
Phillips TJ et al. Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study. ASCO 2024;Abstract 7008.
Poon M et al. Odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal phase II study of ELM-2. ICML 2023;Abstract 93.
Thieblemont C et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin Oncol 2022;41(12):2238-47. Abstract